3,3′,5-三碘-L-甲状腺素-13C6

更新时间：2024-04-08 21:06:53

3,3′,5-三碘-L-甲状腺素-13C6结构式	常用名	3,3′,5-三碘-L-甲状腺素-13C6	英文名	Liothyronine-13C6-1
	CAS号	1213431-76-5	分子量	656.93
	密度	N/A	沸点	N/A
	分子式	₁₃C₆C₉H₁₂I₃NO₄	熔点	N/A
	MSDS	N/A	闪点	9 °C
	符号	GHS02, GHS06, GHS08	信号词	Danger

3,3′,5-三碘-L-甲状腺素-13C6用途

内标3,3´,5--三碘-L-甲状腺原氨酸--13C6（T3-13C6）的Certified Spiking Solution®。3,3′,5-三碘-L-甲状腺原氨酸（T3）是一种甲状腺激素，参与人体生长发育、代谢、体温和心率等多种生理过程。该内标适用于LC-MS/MS法定量检测血清游离T3和总T3水平，以测定由过量T3引起的甲亢。

中文名	3,3′,5-三碘-L-甲状腺素-13C6
英文名	3,3′,5-Triiodo-L-thyronine-13C6 solution

描述	Liothyronie-13C6-1是13C标记的Liothyroine。Liothyronine是一种有效的甲状腺激素受体TRα和TRβ激动剂,hTRα和hTRβ的Kis分别为2.33 nM[1][2]。
相关类别	研究领域 >> 癌症研究领域 >> 内分泌信号通路 >> 其他 >> 甲状腺激素受体
参考文献	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Lin KH, et al. Stimulation of proliferation by 3,3',5-triiodo-L-thyronine in poorly differentiated human hepatocarcinoma cells overexpressing beta 1 thyroid hormone receptor. Cancer Lett. 1994 Oct 14;85(2):189-94.

描述

Liothyronie-13C6-1是13C标记的Liothyroine。Liothyronine是一种有效的甲状腺激素受体TRα和TRβ激动剂,hTRα和hTRβ的Kis分别为2.33 nM[1][2]。

相关类别

研究领域 >> 癌症

研究领域 >> 内分泌

信号通路 >> 其他 >> 甲状腺激素受体

参考文献

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Lin KH, et al. Stimulation of proliferation by 3,3',5-triiodo-L-thyronine in poorly differentiated human hepatocarcinoma cells overexpressing beta 1 thyroid hormone receptor. Cancer Lett. 1994 Oct 14;85(2):189-94.

分子式	₁₃C₆C₉H₁₂I₃NO₄
分子量	656.93
外观性状	liquid

符号	GHS02, GHS06, GHS08
信号词	Danger
危害声明	H225-H301 + H311 + H331-H370
警示性声明	P210-P260-P280-P301 + P310-P311
危险品运输编码	UN1230 - class 3 - PG 2 - Methanol, solution
闪点（华氏）	48.2 °F
闪点（摄氏）	9 °C

Psychometric assessment of the Rat Grimace Scale and development of an analgesic intervention score.

PLoS ONE 9(5) , e97882, (2014)

Our limited ability to assess spontaneous pain in rodent models of painful human conditions may be associated with a translational failure of promising analgesic compounds in to clinical use. If measu...

Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis.

Crit. Rev. Oncol. Hematol. , doi:10.1016/j.critrevonc.2014.04.004, (2014)

Arterial thromboembolic events (ATEs) with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) have emerged as a serious concern, we perform a meta-analysis of randomiz...

Intensity-modulated radiotherapy for stage IVA/IVB nasopharyngeal carcinoma: clinical outcomes and patterns of failure in an endemic area in China.

Strahlenther. Onkol. , (2014)

The purpose of this study was to analyze the mode of relapse patterns and survival of 209 patients with stage IVA and IVB nasopharyngeal carcinoma (NPC).A total of 209 patients who underwent magnetic ...

3,3′,5-三碘-L-甲状腺素-13C6

3,3′,5-三碘-L-甲状腺素-13C6用途

3,3′,5-三碘-L-甲状腺素-13C6名称

3,3′,5-三碘-L-甲状腺素-13C6生物活性

3,3′,5-三碘-L-甲状腺素-13C6物理化学性质

3,3′,5-三碘-L-甲状腺素-13C6安全信息

3,3′,5-三碘-L-甲状腺素-13C6文献45